Global and India Anti-VEGT Drugs Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and India Anti-VEGT Drugs Market Report & Forecast 2024-2034
Anti-VEGF (Vascular Endothelial Growth Factor) drugs are a class of medications used to treat various eye conditions, particularly those affecting the retina and blood vessels at the back of the eye. VEGF is a protein that promotes the growth of new blood vessels. In certain eye diseases, excessive VEGF can contribute to abnormal blood vessel growth and leakage, causing vision problems or loss.
Anti-VEGF drugs work by inhibiting or blocking the activity of VEGF, thus helping to reduce the growth of abnormal blood vessels and fluid leakage within the eye. These drugs are administered directly into the eye using injections.
The global Anti-VEGT Drugs revenue was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during the forecast period (2024-2034).
In India, the Anti-VEGT Drugs revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period (2024-2034).
The global key players of Anti-VEGT Drugs include Genentech (Roche), Regeneron Pharmaceuticals, Novartis, AstraZeneca, Bayer, Abbott, Santen, Pfizer and Sanofi, etc. The global five biggest players hold a share of % in 2022.
This report focuses on global and India Anti-VEGT Drugs market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2024, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for Anti-VEGT Drugs will continue to grow rapidly in the future.
Global Anti-VEGT Drugs Scope and Market Size
Anti-VEGT Drugs market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Anti-VEGT Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2029.
For India market, this report focuses on the Anti-VEGT Drugs market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in India.

Genentech (Roche)
Regeneron Pharmaceuticals
Novartis
AstraZeneca
Bayer
Abbott
Santen
Pfizer
Sanofi
Bristol-Myers Squibb
GlaxoSmithKline
Eli Lilly & Company
Chugai Pharma
Kanghong Pharmaceutical
Segment by Type
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
Oncology
Ophthalmology
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces Anti-VEGT Drugs definition, global sales (volume and revenue), India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Anti-VEGT Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Anti-VEGT Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-VEGT Drugs sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
Anti-VEGF drugs work by inhibiting or blocking the activity of VEGF, thus helping to reduce the growth of abnormal blood vessels and fluid leakage within the eye. These drugs are administered directly into the eye using injections.
The global Anti-VEGT Drugs revenue was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during the forecast period (2024-2034).
In India, the Anti-VEGT Drugs revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period (2024-2034).
The global key players of Anti-VEGT Drugs include Genentech (Roche), Regeneron Pharmaceuticals, Novartis, AstraZeneca, Bayer, Abbott, Santen, Pfizer and Sanofi, etc. The global five biggest players hold a share of % in 2022.
This report focuses on global and India Anti-VEGT Drugs market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2024, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for Anti-VEGT Drugs will continue to grow rapidly in the future.
Global Anti-VEGT Drugs Scope and Market Size
Anti-VEGT Drugs market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Anti-VEGT Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2029.
For India market, this report focuses on the Anti-VEGT Drugs market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in India.

By Company
Genentech (Roche)
Regeneron Pharmaceuticals
Novartis
AstraZeneca
Bayer
Abbott
Santen
Pfizer
Sanofi
Bristol-Myers Squibb
GlaxoSmithKline
Eli Lilly & Company
Chugai Pharma
Kanghong Pharmaceutical
Segment by Type
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
Segment by Application
Oncology
Ophthalmology
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces Anti-VEGT Drugs definition, global sales (volume and revenue), India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Anti-VEGT Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Anti-VEGT Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-VEGT Drugs sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
